POINT Biopharma Plans Indianapolis Manufacturing Facility

Published 6-2-2020

POINT Biopharma, a clinical-stage pharmaceutical company based in Canada, is establishing its first U.S. manufacturing center in Indianapolis. The $25 million project includes the purchase and renovation of an existing 77,000-sf, food-grade structure, with additional funds to be invested in sophisticated cleanroom technologies and packaging systems. Slated for occupancy in mid-2020, the GMP facility will support the production of radioligands for POINT's innovative cancer therapies. The next-generation manufacturing center will be fully operational by 2021.